IMGENEX INDIA Pvt. Ltd., is one of the foremost biotechnology company in the Eastern region of India and was founded by Dr. Sujay Singh, Ph.D., in the year 2004 at Bhubaneswar. IMGENEX India has built a state-of-the-art R&D facility at the Infocity complex. The R&D unit of IMGENEX India was inaugurated in 2005 by Dr. APJ Abdul Kalam, the then Hon’ble President of India and is recognized by the Department of Science and Industrial Research (DSIR), Ministry of Science & Technology, Govt. of India. The R&D Unit of IMGENEX India possesses all the modern equipment for molecular biology, recombinant protein production, cell culture, antibody development and other downstream processes.
The main goal of IMGENEX India is to provide affordable healthcare to less privileged patients. Over the years IMGENEX India has received several grants from the Department of Biotechnology (DBT) that includes SIBRI grant from to develop drugs for osteoporosis using nanotechnology based drug delivery. It is in the early development phase. In addition to this with grants from BIRAC we have helped us to develop a high-yield mammalian expression system in CHO cells that is capable of producing 3-4 g per liter biosimilar Trastuzumab/Herceptin. Other biosimilars in the pipeline includes Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).
In collaboration with National Institute Of Immunohematology, a division of Indian Council Of Medical Research (ICMR), IMGENEX India is developing first indigenous diagnostic kit for detection of beta thalassemia, which should be available soon through ICMR.
IMGENEX India is also developing and validating serological diagnostic reagents and kits for plant viruses affecting horticultural crops under a CRS scheme granted to ICAR-Indian Agricultural Research Institute.
IMGENEX India had received awards as Emerging Company in the Asia-Pacific Region in the year 2011 by Singapore based Bio Spectrum magazine and Emerging Company of the Year 2015 in Bio industry sector in India by Bangalore Bio.
At present, we are building a 14,000 sqft GMP facility in Bhubaneswar, Odisha for production of recombinant therapeutic antibodies and proteins using single use bioreactors.